跳至主要内容
临床试验/NCT00944944
NCT00944944已完成不适用

A Pilot Study Using the Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2009年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
58
试验地点
1
主要终点
To determine if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ)tools detects lower extremity lymphedema symptoms in gynecologic cancer survivors & if it is a feasible assessment tool which can be used in the clinical care setting.

研究概览

简要总结

The purpose of this study is to evaluate if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) truly detects symptoms or signs of lower extremity lymphedema in patients with diagnosed lower extremity lymphedema. Lymphedema is a chronic condition in which fluid accumulates in the tissues of the body. Many cancer survivors are living with discomfort and changes in their activities due to limb swelling following cancer treatment. If the GCLQ is able to do detect signs and symptoms of lymphedema, the investigators hope to use it as a tool in the clinical care setting to help identify women at risk for or with lymphedema. In the future, this could improve clinical care through the use of a more simple and feasible way to identify lower extremity lymphedema than measuring limbs.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Study group of Gynecologic cancer survivors with Lymphedema
  • Documented lower extremity lymphedema
  • History of a primary diagnosis of gynecologic cancer (vulvar, cervical and uterine only)
  • History of surgery for gynecologic cancer including lymph node removal
  • No evidence of disease or active treatment
  • At least 21 years of age
  • Able and willing to provide informed consent
  • English fluency Comparison Group of Gynecologic Cancer Survivors without Lymphedema
  • No history of lower extremity lymphedema or presence of lymphedema confirmed by limb volume measurements at the time of study participation
  • History of a primary diagnosis of gynecologic cancer (vulvar, cervical and uterine only)
  • History of surgery for gynecologic cancer including lymph node removal
  • No evidence of disease or active treatment
  • At least 21 years of age
  • Able and willing to provide informed consent
  • English fluency

排除标准

  • Inability to participate in an informed consent process
  • Patients with a psychiatric disorder precluding response to the survey

结局指标

主要结局

To determine if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ)tools detects lower extremity lymphedema symptoms in gynecologic cancer survivors & if it is a feasible assessment tool which can be used in the clinical care setting.

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

已完成
不适用
ASk Questions in GYnecologic Oncology (ASQ-GYO)Endometrial CancerGestational Trophoblastic DiseaseVaginal CancerOvarian CancerVulvar CancerCervical Cancer
NCT06339827Ira Winer68
Unknown
不适用
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar CancerLymphedemaStage IA Cervical CancerStage IA Uterine Corpus CancerStage IA Vulvar CancerStage IB Cervical CancerStage IB Uterine Corpus CancerStage IB Vulvar CancerStage II Uterine Corpus CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIIA Vulvar CancerStage IIIB Vulvar CancerStage IIIC Vulvar CancerStage IVB Vulvar Cancer
NCT00956670Gynecologic Oncology Group1,055
已完成
不适用
Molecular Staging of Endometrial CancerEndometrial Cancer
NCT00340808National Cancer Institute (NCI)5,492
已完成
不适用
Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast CancerBreast Cancer
NCT00551278Janssen Diagnostics, LLC80
进行中(未招募)
不适用
Estudio aleatorizado del Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer epitelial de ovario - Bevacizumab en Cáncer de OvarioCarcinoma epitelial de ovario, carcinoma peritoneal primario o carcinoma de Trompas de Falopio. Neoplasma maligno de ovario.MedDRA version: 9.1Level: LLTClassification code 10026310Term: Malignant neoplasm of ovary
EUCTR2005-003929-22-ESGRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER DE OVARIO (GEICO)1,520